CD19 and neoplasm: Although CD19 CAR-T therapy has entered clinical trials and has been successful in chronic lymphocytic leukemia, its utility is restricted because of the single antibody, rare tumor-specific single antigen, and susceptibility to cross-reactivity, resulting in damage to healthy cells [97].